Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: Role of Factor XI

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Aprotinin is commonly administered in settings involving cardiopulmonary bypass and liver transplantation to decrease peri-operative bleeding. Thrombelastography has been utilized to monitor coagulation in these settings, and aprotinin delays clot initiation, presumably by inhibiting kallikrein; however, aprotinin also inhibits Factor XI (FXI), a contact system protein. Thus, it was hypothesized that celite-activated thrombelastography coagulation kin-etics would be decreased via aprotinin-mediated FXI inhibition. Methods: Citrated normal plasma and prekallikrein-deficient (<1% normal activity) plasma were exposed to 0, 200, 400 or 800 kallikrein inhibitory units (KIU)/ml (n = 6 per condition). Samples were recalcified and celite-activated in a thrombelastograph, with clot initiation (R, s) determined. To confirm contact system specificity, additional prekallikrein-deficient samples with 0 or 800 KIU/ml aprotinin were activated with tissue factor (n = 4 per condition). Results: Exposure of celite-activated, normal plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 167 ± 14, 253 ± 10, 293 ± 22 and 349 ± 21 s, respectively, which were significantly different from one another (P < 0.05). Exposure of celite-activated, prekallikrein-deficient plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 366 ± 15, 630 ± 64, 698 ± 46 and 850 ± 47 s, respectively, which were significantly different from one another (P < 0.05). There were no significant differences in R values between tissue factor-activated, prekallikrein-deficient plasma samples with 0 or 800 KIU/ml aprotinin. Conclusions: These data support a role for the inhibition of FXI as the mechanism for aprotinin-mediated delayed contact system clot initiation determined by thrombelastography.

Original languageEnglish (US)
Pages (from-to)168-172
Number of pages5
JournalActa Anaesthesiologica Scandinavica
Volume50
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Factor XI
Thrombelastography
Aprotinin
Kallikreins
Prekallikrein
Diatomaceous Earth
Thromboplastin
Cardiopulmonary Bypass
Liver Transplantation
Hemorrhage

Keywords

  • Aprotinin
  • Factor XI
  • Kallikrein
  • Kininogen
  • Thrombelastography

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

@article{41c56bfdc50349259b6d5f2e8e1d54a4,
title = "Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: Role of Factor XI",
abstract = "Background: Aprotinin is commonly administered in settings involving cardiopulmonary bypass and liver transplantation to decrease peri-operative bleeding. Thrombelastography has been utilized to monitor coagulation in these settings, and aprotinin delays clot initiation, presumably by inhibiting kallikrein; however, aprotinin also inhibits Factor XI (FXI), a contact system protein. Thus, it was hypothesized that celite-activated thrombelastography coagulation kin-etics would be decreased via aprotinin-mediated FXI inhibition. Methods: Citrated normal plasma and prekallikrein-deficient (<1{\%} normal activity) plasma were exposed to 0, 200, 400 or 800 kallikrein inhibitory units (KIU)/ml (n = 6 per condition). Samples were recalcified and celite-activated in a thrombelastograph, with clot initiation (R, s) determined. To confirm contact system specificity, additional prekallikrein-deficient samples with 0 or 800 KIU/ml aprotinin were activated with tissue factor (n = 4 per condition). Results: Exposure of celite-activated, normal plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 167 ± 14, 253 ± 10, 293 ± 22 and 349 ± 21 s, respectively, which were significantly different from one another (P < 0.05). Exposure of celite-activated, prekallikrein-deficient plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 366 ± 15, 630 ± 64, 698 ± 46 and 850 ± 47 s, respectively, which were significantly different from one another (P < 0.05). There were no significant differences in R values between tissue factor-activated, prekallikrein-deficient plasma samples with 0 or 800 KIU/ml aprotinin. Conclusions: These data support a role for the inhibition of FXI as the mechanism for aprotinin-mediated delayed contact system clot initiation determined by thrombelastography.",
keywords = "Aprotinin, Factor XI, Kallikrein, Kininogen, Thrombelastography",
author = "Nielsen, {Vance G}",
year = "2006",
month = "2",
doi = "10.1111/j.1399-6576.2006.00935.x",
language = "English (US)",
volume = "50",
pages = "168--172",
journal = "Acta Anaesthesiologica Scandinavica",
issn = "0001-5172",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography

T2 - Role of Factor XI

AU - Nielsen, Vance G

PY - 2006/2

Y1 - 2006/2

N2 - Background: Aprotinin is commonly administered in settings involving cardiopulmonary bypass and liver transplantation to decrease peri-operative bleeding. Thrombelastography has been utilized to monitor coagulation in these settings, and aprotinin delays clot initiation, presumably by inhibiting kallikrein; however, aprotinin also inhibits Factor XI (FXI), a contact system protein. Thus, it was hypothesized that celite-activated thrombelastography coagulation kin-etics would be decreased via aprotinin-mediated FXI inhibition. Methods: Citrated normal plasma and prekallikrein-deficient (<1% normal activity) plasma were exposed to 0, 200, 400 or 800 kallikrein inhibitory units (KIU)/ml (n = 6 per condition). Samples were recalcified and celite-activated in a thrombelastograph, with clot initiation (R, s) determined. To confirm contact system specificity, additional prekallikrein-deficient samples with 0 or 800 KIU/ml aprotinin were activated with tissue factor (n = 4 per condition). Results: Exposure of celite-activated, normal plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 167 ± 14, 253 ± 10, 293 ± 22 and 349 ± 21 s, respectively, which were significantly different from one another (P < 0.05). Exposure of celite-activated, prekallikrein-deficient plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 366 ± 15, 630 ± 64, 698 ± 46 and 850 ± 47 s, respectively, which were significantly different from one another (P < 0.05). There were no significant differences in R values between tissue factor-activated, prekallikrein-deficient plasma samples with 0 or 800 KIU/ml aprotinin. Conclusions: These data support a role for the inhibition of FXI as the mechanism for aprotinin-mediated delayed contact system clot initiation determined by thrombelastography.

AB - Background: Aprotinin is commonly administered in settings involving cardiopulmonary bypass and liver transplantation to decrease peri-operative bleeding. Thrombelastography has been utilized to monitor coagulation in these settings, and aprotinin delays clot initiation, presumably by inhibiting kallikrein; however, aprotinin also inhibits Factor XI (FXI), a contact system protein. Thus, it was hypothesized that celite-activated thrombelastography coagulation kin-etics would be decreased via aprotinin-mediated FXI inhibition. Methods: Citrated normal plasma and prekallikrein-deficient (<1% normal activity) plasma were exposed to 0, 200, 400 or 800 kallikrein inhibitory units (KIU)/ml (n = 6 per condition). Samples were recalcified and celite-activated in a thrombelastograph, with clot initiation (R, s) determined. To confirm contact system specificity, additional prekallikrein-deficient samples with 0 or 800 KIU/ml aprotinin were activated with tissue factor (n = 4 per condition). Results: Exposure of celite-activated, normal plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 167 ± 14, 253 ± 10, 293 ± 22 and 349 ± 21 s, respectively, which were significantly different from one another (P < 0.05). Exposure of celite-activated, prekallikrein-deficient plasma to aprotinin 0, 200, 400 or 800 KIU/ml resulted in R values of 366 ± 15, 630 ± 64, 698 ± 46 and 850 ± 47 s, respectively, which were significantly different from one another (P < 0.05). There were no significant differences in R values between tissue factor-activated, prekallikrein-deficient plasma samples with 0 or 800 KIU/ml aprotinin. Conclusions: These data support a role for the inhibition of FXI as the mechanism for aprotinin-mediated delayed contact system clot initiation determined by thrombelastography.

KW - Aprotinin

KW - Factor XI

KW - Kallikrein

KW - Kininogen

KW - Thrombelastography

UR - http://www.scopus.com/inward/record.url?scp=33644778049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644778049&partnerID=8YFLogxK

U2 - 10.1111/j.1399-6576.2006.00935.x

DO - 10.1111/j.1399-6576.2006.00935.x

M3 - Article

C2 - 16430537

AN - SCOPUS:33644778049

VL - 50

SP - 168

EP - 172

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 2

ER -